Author:
Becker Ann-Katharina,Puladi Behrus,Xie Kunpeng,Cassataro Angela,Götzl Rebekka,Hölzle Frank,Beier Justus P.,Knüchel-Clarke Ruth,Braunschweig Till
Abstract
Abstract
Background
Liposarcomas are among the most common mesenchymal malignancies. However, the therapeutic options are still very limited and so far, targeted therapies had not yet been established. Immunotherapy, which has been a breakthrough in other oncological entities, seems to have no efficacy in liposarcoma. Complicating matters further, classification remains difficult due to the diversity of morphologies and nonspecific or absent markers in immunohistochemistry, leaving molecular pathology using FISH or sequencing as best options. Many liposarcomas harbor MDM2 gene amplifications. In close relation to the gene locus of MDM2, HER3 (ERBB3) gene is present and co-amplification could occur. Since the group of HER/EGFR receptor tyrosine kinases and its inhibitors/antibodies play a role in a broad spectrum of oncological diseases and treatments, and some HER3 inhibitors/antibodies are already under clinical investigation, we hypothesized that in case of HER3 co-amplifications a tumor might bear a further potential therapeutic target.
Methods
We performed FISH analysis (MDM2, DDIT3, HER3) in 56 archived cases and subsequently performed reclassification to confirm the diagnosis of liposarcoma.
Results
Next to 16 out of 56 cases needed to be re-classified, in 20 out of 54 cases, a cluster-amplification of HER3 could be detected, significantly correlating with MDM2 amplification. Our study shows that the entity of liposarcomas show specific molecular characteristics leading to reclassify archived cases by modern, established methodologies. Additionally, in 57.1% of these cases, HER3 was cluster-amplified profusely, presenting a putative therapeutic target for targeted therapy.
Conclusion
Our study serves as the initial basis for further investigation of the HER3 gene as a putative therapeutic target in liposarcoma.
Funder
Ludwig-Maximilians-Universität München
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End results database. Pediatr Blood Cancer. 2011;57:943–9. https://doi.org/10.1002/pbc.23252.
2. Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49:684–95. https://doi.org/10.1016/j.ejca.2012.09.011.
3. Yang Z, Zheng R, Zhang S, et al. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019;16:565–74. https://doi.org/10.20892/j.issn.2095-3941.2019.0041.
4. WHO. (2020) Soft tissue and bone tumours, 5th edition. World Health Organization classification of tumours series, vol. 3, 5th ed. World Health Organization; International Agency for Research on Cancer, Geneva, Lyon.
5. Creytens D. What’s new in adipocytic neoplasia? Virchows Arch. 2020;476:29–39. https://doi.org/10.1007/s00428-019-02652-3.